About Solstice

Learn more about the SOLSTICE clinical research study.

SOLSTICE is a clinical research study designed to explore an investigational drug—maribavir—in transplant recipients whose CMV infections are not responding to current antiviral drugs.

The main goal of the 22-week study is to see if maribavir works to clear CMV infections from transplant recipients who are not responding to current treatments. Participants will receive either maribavir or the study doctor’s treatment of choice for 8 weeks.

The study doctor or staff will then assess participants for an additional 12 weeks after treatment, to confirm that they remain free of CMV infection (no virus detected in blood).


Find out if you may qualify for the SOLSTICE research study now. Learn More >